Citations |
ACS Appl Mater Interfaces. 2022 May 11.<br/>Acs Biomater Sci Eng. 2022 Mar 1.<br/>Acs Biomater Sci Eng. 2023 Jan 20.<br/>Acta Pharm Sin B. 2023 May 16.<br/>Adv Healthc Mater. 2021 Feb 15;e2002103.<br/>Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.<br/>Adv Sci (Weinh). 2023 Nov 29:e2303088.<br/>Adv Sci (Weinh). 2024 May 20:e2307216.<br/>Adv Ther. 2024 April 30.<br/>Anal Chem. 2017 Oct 17;89(20):10841-10849.<br/>Ann Surg Oncol. 2024 Jan 4.<br/>Bioact Mater. 14 August 2022.<br/>Bioact Mater. 2021 Jun 1.<br/>Bioact Mater. 2023 Aug.<br/>Biochem Biophys Rep. September 2022, 101299.<br/>Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577.<br/>Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140.<br/>Biochem Biophys Res Commun. 2023<br/>Bioengineered. 2022 Apr;13(4):8747-8758.<br/>Bioengineering (Basel). 2020 Dec 18;7(4):164.<br/>Biology (Basel). 2023, 12(6), 888.<br/>Biomater Adv. 2023 Dec 26, 213751.<br/>Biomaterials. 2020 May;240:119849.<br/>Biomaterials. 2020 Nov;258:120284.<br/>Biomaterials. 2024 Jan 1:305:122462.<br/>Biomed Pharmacother. September 2022, 113465.<br/>Biomed Res Int. 2021 May 15.<br/>bioRxiv. 2020 Aug.<br/>bioRxiv. 2020 Mar.<br/>bioRxiv. 2023 Dec 6.<br/>bioRxiv. 2023 Feb 24.<br/>bioRxiv. 2023 Jul 1.<br/>bioRxiv. 2023 Jun 22.<br/>bioRxiv. 2023 Jun 28.<br/>bioRxiv. 2023 Mar 1.<br/>bioRxiv. 2024 Feb 18.<br/>bioRxiv. January 16, 2022.<br/>Biosci Biotechnol Biochem. 2021 Jul 23;zbab136.<br/>BMC Cancer. 2023 Jun 22;23(1):577.<br/>BMC Pulm Med. 2023 Dec 13;23(1):505.<br/>BMC Urol. 2021 Jan 6;21(1):5.<br/>Bone Res. 2022 Jan 3;10(1):1.<br/>Brain Res. 15 December 2021, 147684.<br/>Can Respir J. 10 Oct 2022.<br/>Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12.<br/>Cancer Cell. 2024 May 20:S1535-6108(24)00164-8.<br/>Cancer Lett. 2019 Apr 28;448:117-127.<br/>Cancer Res. 2022 Dec 8;CAN-22-2370.<br/>Cancers (Basel). 2021, 13(13), 3282.<br/>Cell Biochem Biophys. 2023 Oct 6.<br/>Cell Biosci. 2024 May 22;14(1):65.<br/>Cell Death Dis. 2022 Aug 24;13(8):730.<br/>Cell Death Dis. 2023 Apr 20;14(4):280.<br/>Cell Death Discov. 2023 Jan 25;9(1):32.<br/>Cell Discov. 2021 Apr 19;7(1):25.<br/>Cell Discov. 2022 Apr 19;8(1):35.<br/>Cell Prolif. 2022 Aug 3;e13320.<br/>Cell Prolif. 2022 Mar 11;e13209.<br/>Cell Prolif. 2024 Jan 12:e13599.<br/>Cell Regen. 2020 Sep 3;9(1):15.<br/>Cell Rep Med. 2023 Jan 10;100911.<br/>Cell Rep Methods. 2024 May 8:100777.<br/>Cell Rep. 2023 May 2;42(5):112445.<br/>Cell Rep. 2023 Oct 5;42(10):113213.<br/>Cell Rep. 2019 Jan 8;26(2):407-414.e5.<br/>Cell Res. 2023 Jul 17.<br/>Cell Signal. 2024 May 8:111223.<br/>Cell Stem Cell. 2020 Oct 1;27(4):646-662.e7. <br/>Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10.<br/>Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.<br/>Cells. 2023 Dec 30, 13(1), 81.<br/>Chem Biol Interact. 17 August 2021, 109625.<br/>Chem Eng J. 1 January 2023, 138737.<br/>Chem Eng J. 2024 Apr 1, 485, 149884.<br/>Circ Res. 2020 Oct 9;127(9):1182-1194.<br/>Clin Mol Hepatol. 2023 Feb 20.<br/>Compos Part B-Eng. 2023 Apr 6, 110711.<br/>Connect Tissue Res. 2022 Jan 12;1-10.<br/>EMBO Mol Med. 2022 Dec 13;e16373.<br/>Environ Pollut. 2020 Jun;261:114153.<br/>Environ Toxicol Pharmacol. 2023 Oct 20:104301.<br/>Eur J Cell Biol. 2024 May 28;103(2):151427.<br/>Eur J Immunol. 2022 Aug;52(8):1308-1320.<br/>Exp Mol Med. 2021 Sep 21.<br/>Exp Mol Med. 2023 Jun 19.<br/>Exp Ther Med. 2021 Feb 3.<br/>F1000Research. 03 Aug 2022.<br/>FASEB J. 03 October 2022.<br/>Front Cell Dev Biol. 2021 Jun 24;9:670825.<br/>Front Med. 2021 Sep 23;8:746298.<br/>Front Physiol. 2020 Jun 30;11:669.<br/>Gut Microbes. 2022, 14(1): 2139978.<br/>Harvard Medical School LINCS LIBRARY<br/>Hum Mol Genet. 2022 Aug 10;ddac190.<br/>Immunity. 2022 Mar 15;S1074-7613(22)00124-8.<br/>Int J Biol Sci. 2022 Aug 29;18(14):5459-5474.<br/>Int J Mol Sci. 2022, 23(23), 14637<br/>Int J Mol Sci. 2023 Oct 31, 24(21), 15804.<br/>Int J Mol Sci. 2024 Apr 9, 25(8), 4138.<br/>iScience. 19 October 2021, 103303.<br/>iScience. 2023 Aug 26.<br/>J Biol Chem. 2023 Oct 19:105361.<br/>J Biol Eng. 2024 Jan 16;18(1):7.<br/>J Biosci Bioeng. 2020 Dec 23;S1389-1723(20)30432-1.<br/>J Bone Oncol. October 2021, 100391.<br/>J Cell Mol Med. 2020 Jul;24(14):8179-8193.<br/>J Clin Invest. 2022 Jan 25;e154993.<br/>J Clin Med. 2019 Oct 21;8(10):1751.<br/>J Immunother Cancer. 2024 Apr 19;12(4):e008628.<br/>J Med Chem. 2019 Jul 11;62(13):6083-6101.<br/>J Neuroinflammation. 2024 Apr 10;21(1):88.<br/>J Neurosci. 2021 Jan 20;41(3):392-407.<br/>J Transl Med. 2023 Oct 10;21(1):711.<br/>J Virol. 2021 Feb 24;95(10):e02436-20.<br/>J Virol. 2023 Apr 27;e0177022.<br/>JCI Insight. 2024 Apr 23:e171916.<br/>Life Sci. 2020 Apr 1;246:117419.<br/>Life. 2021, 11(8), 789.<br/>Mat Sci Eng C-Mater. 2021, 111939.<br/>Med Sci Monit. 2018 May 27;24:3514-3523. <br/>Methods Mol Biol. 2022 Dec 15.<br/>Methods Mol Biol. 2023;2683:53-68.<br/>Mol Cancer. 2024 Jun 8;23(1):125.<br/>Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.<br/>Mol Med. 2023 Oct 20;29(1):139.<br/>Mol Neurobiol. 2024 Mar 20.<br/>Nat Cell Biol. 2022 Jun;24(6):858-871.<br/>Nat Commun. 2022 Apr 19;13(1):2028.<br/>Nat Commun. 2022 Jun 1;13(1):3060.<br/>Nat Commun. 2022 Sep 6;13(1):5237.<br/>Nat Commun. 2023 Apr 6;14(1):1912.<br/>Nat Commun. 2023 Aug 8;14(1):4779.<br/>Nat Commun. 2024 Feb 19;15(1):1493.<br/>Nat Commun. 2024 Feb 7;15(1):1150.<br/>Nat Commun. 2024 Mar 11;15(1):2192.<br/>Nat Commun. 2024 May 30;15(1):4590.<br/>Nat Genet. 2024 Feb;56(2):294-305.<br/>Neurotherapeutics. 2021 Jan 21.<br/>NPJ Regen Med. 2022 Jun 16;7(1):31.<br/>Nutr Metab. 2020 Oct 26;17:91.<br/>Oncogene. 2023 Aug 31.<br/>Oncol Rep. 2020 Sep;44(3):1266-1274.<br/>Oncotarget. 2017 Jul 31;8(47):82506-82530.<br/>Patent. US20210284970A1.<br/>Patent. US20220177852A1.<br/>Patent. US20220267735A1.<br/>Patent. US20240018470A1.<br/>Pharmacol Res. 2022 Dec 16;187:106615.<br/>Phytother Res. 2024 Feb 15.<br/>Protein Cell. 2021 Feb;12(2):107-127.<br/>Reprod Toxicol. 2023 Dec 12:123:108522.<br/>Research (Wash D C). 2023 Oct 24.<br/>Research Square Preprint. 2021 Jan.<br/>Research Square Preprint. 2021 May.<br/>Research Square Preprint. 2021 Oct.<br/>Research Square Preprint. 2022 Jan.<br/>Research Square Preprint. 2022 Jun.<br/>Research Square Preprint. 2023 May 30.<br/>Respir Res. 2022 Mar 25;23(1):70.<br/>Sci Adv. 2023 Dec 22;9(51):eadi5683.<br/>Sci Adv. 2023 Oct 27;9(43):eadg6686.<br/>Sci Rep. 2017 Dec 19;7(1):17770.<br/>Sci Rep. 2021 Dec 7;11(1):23564.<br/>Sci Rep. 2019 Dec 17;9(1):19301. <br/>Sci Total Environ. 2020 Jul 10;725:138433.<br/>Sci Total Environ. 2022 May 18;838(Pt 2):155811.<br/>Small. 2021 Jun 8;e2100546.<br/>Small. 2021 Nov 2;e2104773.<br/>SSRN. 2023 Feb 6.<br/>SSRN. 2024 Jan 22.<br/>STAR Protoc. 2021 Nov 5;2(4):100881.<br/>STAR Protoc. 2023 Feb 3;4(1):102092.<br/>Stem Cell Res Ther. 2019 May 31;10(1):155.<br/>Stem Cell Res. 2021, 102157.<br/>Stem Cell Res. 2021, 102217.<br/>Stem Cell Res. 2022 Sep 15;64:102916.<br/>Stem Cell Res. 2024 Feb 3:76:103327.<br/>Stem Cell Res. 2024 Mar 24, 103399.<br/>Theranostics. 2022 Mar 21;12(6):2908-2927.<br/>Theranostics. 2022 Mar 28;12(7):3131-3149.<br/>Theranostics. 2022; 12(17): 7250-7266<br/>Theranostics. 2023 May 27;13(10):3290-3309.<br/>Toxicology. 2020 Oct;443:152573.<br/>Vaccines. 2023 May 17, 11(5), 993.<br/>Virology. 2023 May 3;583:45-51.<br/>Am J Physiol Cell Physiol. 2023 May 1.<br/>Biochem Biophys Res Commun. 2021 Mar 18;552:142-149.<br/>Biomaterials. 2021, 120684.<br/>Biomolecules. 2023, 13(1), 69.<br/>bioRxiv. 2023 Dec 22.<br/>bioRxiv. 2023 Feb 16.<br/>bioRxiv. 2024 Feb 1.<br/>bioRxiv. 2024 Feb 27.<br/>bioRxiv. 2024 Jan 5.<br/>bioRxiv. April 21, 2022.<br/>Breast Cancer Res. 2021 Aug 3;23(1):82.<br/>Cancers (Basel). 2022 May 17;14(10):2463.<br/>Cancers (Basel). 2023, 15(3), 931.<br/>cell analysis. 2020 Aug.<br/>Cell Mol Gastroenterol Hepatol. 2022 Nov 24;S2352-345X(22)00238-7.<br/>Cell Rep. 2024 Jan 9;43(1):113668.<br/>Cell Rep. 2024 Mar 1;43(3):113892.<br/>Cell Rep. 2024 May 10;43(5):114206.<br/>Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7. <br/>Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12. <br/>Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8.<br/>Cell Stem Cell. 2022 May 5;29(5):776-794.e13.<br/>Cell Stem Cell. 2022 Oct 6;29(10):1475-1490.e6.<br/>Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8.<br/>Curr Protoc Cell Biol. 2018 Dec;81(1):e62.<br/>Curr Protoc. 2023 Oct;3(10):e915.<br/>Environ Pollut. 2024 Mar 8:123743.<br/>Environ Sci Technol. 2024 Apr 30.<br/>Food Chem Toxicol. 2020 Jan;135:111015.<br/>Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):1. <br/>iScience. 2022 Dec 26;26(1):105898.<br/>iScience. 2024 Feb 5;27(3):109111.<br/>J Adv Res. 2023 Oct 6:S2090-1232(23)00299-0.<br/>J Adv Res. 2024 May 8:S2090-1232(24)00184-X.<br/>J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9.<br/>J Biol Chem. 2022 Aug 12;102374.<br/>J Biol Chem. 2024 Feb 1:105714.<br/>J Environ Sci. 2023 Feb 23.<br/>J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. <br/>J Hazard Mater. 2020 Jul 5;393:122440.<br/>J Hazard Mater. 2021 Apr 5;407:124387.<br/>J Hazard Mater. 2021 Jan 5;401:123341.<br/>JCI Insight. 2023 Nov 8;8(21):e167874.<br/>Life Sci. 2023 Jan 18;316:121404.<br/>Microvasc Res. 2023 Sep 28:151:104611.<br/>Nat Commun. 2023 Nov 27;14(1):7783.<br/>Nat Protoc. 2021 Jan;16(1):352-382.<br/>Nat Protoc. 2023 Feb 15.<br/>Nature. 2022 Jan;601(7894):600-605.<br/>Nature. 2022 Nov;611(7936):603-613.<br/>Nutrients. 2023 Feb 9;15(4):887.<br/>Patent. US20180263995A1.<br/>Patent. US20220062272A1.<br/>PLoS One. 2024 Feb 7;19(2):e0295030.<br/>Research Square Preprint. 2020 Aug 20;rs.3.rs-62758.<br/>Sci Adv. 2021 Sep 17;7(38):eabb5933.<br/>Sci Total Environ. 2023 Dec 30:913:169702.<br/>Science. 2020 Dec 4;370(6521):eaay2002.<br/>STAR Protoc. 16 December 2022, 101786.<br/>STAR Protoc. 2022 Sep 26;3(4):101720.<br/>STAR Protoc. 2023 Jul 9;4(3):102431.<br/>STAR Protoc. 2023 Nov 16;4(4):102683.<br/>Stem Cell Res. October 2021, 102544.<br>[1]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.<br/>[2]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332-5.<br/>[3]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51.<br/>[4]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36.<br/>[5]Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17(2):222-227.<br/>[6]Kan L, et al. Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells. PLoS One. 2015;10(12):e0144513. Published 2015 Dec 8.<br/>[7]Zhang L, et al. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One. 2011;6(3):e18271. Published 2011 Mar 28.<br/>[8]Svoboda KK, et al. ROCK inhibitor (Y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn. 2004;229(3):579-590. |
Product Description |
Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7]. |